Vertex puts a blockbuster valuation on its CRISPR deal

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 20, 2021 at 11:22 AM.

  1. #1 cafead, Apr 20, 2021 at 11:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,057
    Likes Received:
    3
    via The third iteration of Vertex and Crispr’s collaboration over CTX001, a gene-editing therapy for rare blood clotting disorders, shows how hopes for the project have ballooned. Vertex is paying $900m up front, plus a potential $200m milestone on first approval, to up its share of profits and costs from 50% to 60%.

    article source
     
    Quote

Reply to Thread